Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRINCIPAL trial of nivolumab with palliative radiotherapy in previously treated non-small cell lung cancer
jRCTs051180174Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Primary endpoint: Response rate outside the radiation field. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051180174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180174.